CBD Guide
  • Home
  • Education
  • Guides
  • Reviews
  • News
No Result
View All Result
  • Home
  • Education
  • Guides
  • Reviews
  • News
No Result
View All Result
CBD Guide
No Result
View All Result
Home Learn About CBD

Psychedelics Group Raises $30 Million From Execs At GoDaddy, SpaceX And Others For MDMA Study

Jean Martinez by Jean Martinez
August 21, 2020
in Learn About CBD, News
0 0
0
Psychedelics Group Raises $30 Million From Execs At GoDaddy, SpaceX And Others For MDMA Study
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

The nation’s leading psychedelics research organization announced on Thursday that it has raised $30 million in donations—including from several notable business leaders outside the drug policy realm—that will enable it to complete a study on using MDMA to treat post-traumatic stress disorder (PTSD).

The Multidisciplinary Association for Psychedelic Studies (MAPS) said it will use those funds to conduct a Phase 3 trial on the substance, which is commonly called ecstasy, in hopes of gaining approval from the Food and Drug Administration (FDA). The federal agency has already designated MDMA as a “breakthrough therapy” based on findings from the group’s earlier trials.

About 2,500 individual donors helped MAPS reach their fundraising goal within six months. Here are some of the notable contributors:

-Bob Parsons, founder of GoDaddy ($2 million)

-Blake Mycoskie, founder of TOMS Shoes ($1 million)

-John Gilmore, cofounder of Electronic Frontier Foundation ($1 million)

-David Bronner, CEO of Dr. Bronner’s ($800,000)

-Joby Pritzker, managing director of Tao Capital Partners, board member of Marijuana Policy Project and cousin of Illinois Gov. J.B. Pritzker ($3 million)

-Steve Jurvetson, board member of SpaceX and Tesla ($2.6 million)

-Tim Ferriss, tech investor, author and podcaster ($1 million)

Ferriss played a significant role in the fundraising campaign’s success, helping to secure an initial $10 million in philanthropic donations for a challenge grant.

During a press conference, MAPS staff and donors talked about the challenges of fundraising amid the coronavirus pandemic, but they expressed optimism that, with this funding, they are nearing the finish line to complete the Phase 3 trial and provide PTSD patients with legal access to MDMA.

MAPS says they hope to be granted FDA approval as early as 2022.

Asked about the role that the localized psychedelics reform movement might have played in the fundraising campaign, MAPS Founder Rick Doblin told Marijuana Moment that their research objectives and the activists’ legislative objectives have complemented each other.

“I really think that the movements are in parallel,” he said. “The decrim efforts further help to destigmatize and make this research more comfortable and help people feel more comfortable seeking out therapy with psychedelics.”

That said, Doblin noted that “the decrim movement has only taken place after we’ve made a lot of progress with the research—and also the Hopkins team, the NYU teams, the other teams that have worked with psilocybin,” referring to studies from universities, including Johns Hopkins, which last year launched the nation’s first center devoted exclusively to studying psychedelic drugs.

“That kind of preparation then changed a lot of peoples’ attitudes and then they moved towards decrim,” he said. “I think that does help. In fact, we’ve had some indications that that changing of attitudes has made it more comfortable, you could say, for regulators to move forward.”

Joe Green, cofounder of the Psychedelic Science Funders Collaborative, which partnered with MAPS on the fundraising campaign said in a press release that “FDA approval of MDMA-assisted therapy for PTSD could ultimately help millions of people, and that alone is a world-changing impact.”

“We also believe this could be a tipping point for psychedelic medicine overall, leading to a mainstream understanding that psychedelic therapy has the potential to help treat many of the defining mental health crises of our time,” he said.

Also helping to grease the wheels toward expanding psychedelics access are other studies showing therapeutic potential. For example, a scientific review published last year found that “MDMA-assisted psychotherapy demonstrated a high rate of clinical response, remission, with a large effect size at reducing the symptoms of PTSD.”

Earlier this year, a federal commission tasked with developing recommendations to improve mental health treatment for military veterans released a report advising that Congress and the executive branch promote research into the therapeutic potential of marijuana and psychedelics such as psilocybin mushrooms and MDMA.

Researchers at Johns Hopkins also recently announced that they will be collaborating with a Denver-based organization to collect surveys from people about their “real-world” experiences with psilocybin mushrooms.

There are signs that the resurgence of psychedelic science is having an effect on the political world as well.

Rep. Joe Kennedy III (D-MA), who was formerly a staunch opponent to cannabis reform, said during a virtual town hall event this month that he’s been “diving into some of the issues around the medicinal use of certain psychedelics that, at least at this point, show some promise with regards to addressing issues in depression and particularly PTSD.”

As researchers and regulators work to get certain psychedelic medications to patients, activists across the country are pushing to reform laws governing entheogenic substances.

A measure to effectively decriminalize a wide range of psychedelics has officially qualified for the November ballot in Washington, D.C.

In May 2019, Denver became the first U.S. city to decriminalize psilocybin, with the approval of a local ballot measure. Soon after, officials in Oakland, California, decriminalized possession of all plant- and fungi-based psychedelics. The City Council in Santa Cruz, California, voted to make the enforcement of laws against psychedelics among the city’s lowest enforcement priorities in January.

Oregon’s secretary of state confirmed last month that separate measures to legalize psilocybin therapy and decriminalize possession of all drugs while expanding treatment services will appear on the November ballot.

Canada’s health minister recently granted exemptions allowing certain cancer patients to legally use psilocybin for end-of-life care.

Photo by Pretty Drugthings on Unsplash.

The post Psychedelics Group Raises $30 Million From Execs At GoDaddy, SpaceX And Others For MDMA Study appeared first on Marijuana Moment.

This content has been curated and re-published from MarijuanaMoment.net. Please click the link below to view this content from the original source.

Original Source: Psychedelics Group Raises $30 Million From Execs At GoDaddy, SpaceX And Others For MDMA Study

Content Credits: Originally written by Kyle Jaeger and published to MarijuanaMoment.net on 2020-08-20 19:28:02.

Tags: HealthResearch
Previous Post

Hempcrete: How Sustainable Construction Could Change the World

Next Post

Appeal Moves Forward in ‘Woodstock’ Cannabis Trademark Dispute

Related Posts

Wyoming Tribe Moves Toward Hemp and Medical Cannabis Legalization
News

Wyoming Tribe Moves Toward Hemp and Medical Cannabis Legalization

August 31, 2020
Oklahoma to Revoke Testing Lab’s License Amid Scandal
News

Oklahoma to Revoke Testing Lab’s License Amid Scandal

August 30, 2020
Hemp-Based Burger Announced by Fake Meat Startup
News

Hemp-Based Burger Announced by Fake Meat Startup

August 29, 2020
Florida Adds Edibles to Medical Cannabis Program
News

Florida Adds Edibles to Medical Cannabis Program

August 28, 2020
Most Legal Marijuana States Had Fewer Vaping-Related Lung Injuries, Study Finds
Learn About CBD

Most Legal Marijuana States Had Fewer Vaping-Related Lung Injuries, Study Finds

August 27, 2020
Mitch McConnell Recommends Hemp-Based Face Masks
News

Mitch McConnell Recommends Hemp-Based Face Masks

August 27, 2020
Next Post
Appeal Moves Forward in ‘Woodstock’ Cannabis Trademark Dispute

Appeal Moves Forward in ‘Woodstock’ Cannabis Trademark Dispute

Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Recent Posts

  • Wyoming Tribe Moves Toward Hemp and Medical Cannabis Legalization
  • Oklahoma to Revoke Testing Lab’s License Amid Scandal
  • Hemp-Based Burger Announced by Fake Meat Startup
  • Florida Adds Edibles to Medical Cannabis Program
  • Most Legal Marijuana States Had Fewer Vaping-Related Lung Injuries, Study Finds

Recent Comments

  • Jean Martinez on Colorado Gov. Signs Cannabis Social Equity Bill
  • kiran on Colorado Gov. Signs Cannabis Social Equity Bill

Archives

  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
CBD Guide

© 2020 CBDGuide.io, All Rights Reserved.

Site Navigation

  • Affiliate Disclaimer
  • Privacy Policy
  • Terms of Use
  • Contact us

Follow Us

No Result
View All Result
  • Home
  • Education
  • Guides
  • Reviews
  • News

© 2020 CBDGuide.io, All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
0
0
Would love your thoughts, please comment.x
()
x
| Reply